Room for improvement in the follow-up for unilateral headache with autonomic symptoms

Knut Hagen, specialist in neurology, medical adviser for the Department of Research, St Olav's Hospital, Trondheim University Hospital, and professor at the Norwegian University of Science and Technology (NTNU).

The author has completed the ICMJE form and declares the following conflicts of interest: he has received funding for travel from Teva and fees from the Centre for Patient-reported Outcomes Data for work on data quality.

Bendik S. Winsvold, specialist in neurology and senior consultant and senior researcher at the Department of Neurology, Oslo University Hospital. He is a department head at the Norwegian Centre for Headache Research at the Norwegian University of Science and Technology (NTNU).

The author has completed the ICMJE form and declares no conflicts of interest.

Marte-Helene Bjørk, specialist in neurology and senior consultant at the Department of Neurology, Haukeland University Hospital, and professor at the University of Bergen. She is deputy head of the Norwegian Centre for Headache Research at the Norwegian University of Science and Technology (NTNU).

The author has completed the ICMJE form and declares the following conflicts of interest: she has received speaker fees and consultancy fees from Lundbeck and Pfizer and consultancy fees from Novartis and Eisai.

Erling Tronvik, specialist in neurology and senior consultant at the Department of Neurology, St Olav's Hospital, Trondheim University Hospital, and head of the Norwegian Centre for Headache Research at the Norwegian University of Science and Technology (NTNU).

The author has completed the ICMJE form and declares the following conflicts of interest: he has received speaker and/or consultancy fees from Novartis, Eli Lilly, AbbVie, TEVA, Roche, Lundbeck, Pfizer and Biogen. He holds shares and intellectual property rights in Nordic Brain Tech AS, Keimon Medical AS and Man & Science. He has received research funding from the Research Council of Norway, the Liaison Committee for Education, Research and Innovation, the Dam Foundation, the EU, Nordic AI and KlinBeForsk.

Laila Bratterud Mathiesen, general secretary of Headache Norway and user representative at the Norwegian Centre for Headache Research at the Norwegian University of Science and Technology (NTNU).

The author has completed the ICMJE form and declares no conflicts of interest.

Hilde Karen Ofte, specialist in neurology and senior consultant at the Department of Neurology, Nordland Hospital Trust in Bodø.

The author has completed the ICMJE form and declares no conflicts of interest.

Christofer Lundqvist, specialist in neurology and senior consultant at Department of Neurology and Clinical Neurophysiology, Akershus University Hospital and professor II at the University of Oslo.

The author has completed the ICMJE form and declares the following conflicts of interest: he has received speaker fees from Novartis AS, Lundbeck, Roche, AbbVie and Teva, and acted as an adviser in research studies on eptinezumab funded by Lundbeck and as a medical adviser for AbbVie Pharma.

Julie Sønnervik, specialist in neurology and doctor at the Hodeverket Headache Clinic. She is a member of reference groups for the resource network for headaches.

The author has completed the ICMJE form and declares the following conflicts of interest: she has received consultancy fees from AbbVie, speaker fees from Pfizer and Teva, and funding for travel from Teva.

Nina Bäcklund, register coordinator in the Norwegian Quality Register for Severe Primary Headaches and study nurse at the Norwegian Centre for Headache Research.

The author has completed the ICMJE form and declares the following conflict of interest: she has received funding for travel from Teva.